A share price of Adaptimmune Therapeutics Plc ADR [ADAP] is currently trading at $0.29, down -1.37%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ADAP shares have gain 14.92% over the last week, with a monthly amount glided 18.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] stock has seen the most recent analyst activity on July 30, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $4. Previously, Scotiabank started tracking the stock with Sector Outperform rating on May 30, 2024, and set its price target to $3.15. On March 24, 2023, Bryan Garnier initiated with a Buy rating and assigned a price target of $3.60 on the stock. Guggenheim upgraded its rating to a Buy but stick to its price target of $5 on January 03, 2023. Mizuho upgraded its rating to a Buy but $9 remained the price target by the analyst firm on November 09, 2022. Barclays started tracking with a Underweight rating for this stock on May 28, 2021, and assigned it a price target of $4. In a note dated April 22, 2020, Mizuho initiated an Neutral rating and provided a target price of $3 on this stock.
Adaptimmune Therapeutics Plc ADR experienced fluctuations in its stock price throughout the past year between $0.20 and $1.48. Currently, Wall Street analysts expect the stock to reach $2.83 within the next 12 months. Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] shares were valued at $0.29 at the most recent close of the market. An investor can expect a potential return of 875.86% based on the average ADAP price forecast.
Analyzing the ADAP fundamentals
Trailing Twelve Months sales for Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] were 180.20M which represents 28.87% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -0.36%, Pretax Profit Margin comes in at -0.38%, and Net Profit Margin reading is -0.39%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -1.86 and Total Capital is -0.61. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.62.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] is 2.02. Also, the Quick Ratio is 1.79, while the Cash Ratio stands at 0.8. Considering the valuation of this stock, the price to sales ratio is 0.41.
Transactions by insiders
Recent insider trading involved Norry Elliot, Chief Medical Officer, that happened on Jan 17 ’25 when 5584.0 shares were sold. Chief Patient Supply Officer, Lunger John completed a deal on Jan 17 ’25 to sell 5584.0 shares. Meanwhile, Chief Operating Officer Bertrand William C JR sold 5584.0 shares on Jan 17 ’25.
